Inhibitori interleukina-6 u liječenju reumatoidnog artritisa

master's thesis

• Title (english): Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
• Author: Ema Kuhar
• Mentor: Porin Perić (mentor)
• Committee member: Iva Žagar (predsjednik povjerenstva)
• Committee member: Marija Bakula (član povjerenstva)
• Committee member: Porin Perić (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; Zagreb
• Defense date and country: 2024-07-12, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Physical Medicine and Rehabilitation

Abstract

Reumatoidni artritis relativno je česta bolest te se smatra jednom od najčešćih oblika autoimunih bolesti sa zahvaćanjem zglobova. Od reumatoidnog artritisa boluje oko 0.5-1% svjetske populacije. Kontinuirani razvoj i unaprjeđenje lijekova za RA stoga su ključni za poboljšanje života oboljelih i smanjenje socijalno-ekonomskog tereta ove bolesti. Interleukin-6 signalni put od izuzetnog je značaja u upalnim i imunološkim procesima što ga čini i jednim od centralnih ciljeva u razvijanju lijekova za upalne bolesti među kojima je i RA. Istraživanje IL-6 citokina započelo je još 1980-ih, a s njim je započelo i otkrivanje raznih terapijskih mogućnosti u njegovom signalnom putu. Prvi biološki lijek, tocilizumab, odobren je za liječenje u EU još 2010. godine te pokazuje jako dobre rezultate što je potaknulo daljnji razvoj inhibitora IL-6 kao obećavajuće terapije za RA.

Abstract (english)

Rheumatoid arthritis is a relatively common disease and is considered one of the most prevalent forms of autoimmune diseases affecting the joints. Approximately 0.5-1% of the world's population suffers from rheumatoid arthritis. Continuous development and improvement of treatments for RA are therefore crucial to enhance the quality of life for patients and reduce the socio-economic burden of this disease. The interleukin-6 signaling pathway plays a pivotal role in inflammatory and immune processes, making it a central target in the development of therapies for inflammatory diseases, including RA. Research on IL-6 cytokine began in the 1980s, leading to the discovery of various therapeutic possibilities within its signaling pathway. The first biological drug, tocilizumab, was approved for treatment in the EU as early as 2010, demonstrating outstanding results that spurred further development of IL-6 inhibitors as promising therapies for RA.

• Keywords: Ključne riječi: reumatoidni artritis; interleukin-6; inhibitori interleukina-6; tocilizumab
• Keywords (english): Keywords: rheumatoid arthritis; interleukin-6; interleukin-6 inhibitors; tocilizumab
• Language: croatian
• URN:NBN: urn:nbn:hr:105:899568
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2024-07-02 11:50:43